Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer [0.03%]
贝伐单抗联合FOLFOXIRI与贝伐单抗联合mFOLFOX6一线治疗转移性结直肠癌的疗效成本分析
Tong Liu,Yao Yao,Bingjie Liu et al.
Tong Liu et al.
Objectives: We first evaluated thecost-effectiveness of the FOLFOXIRI plus bevacizumab versus mFOLFOX6 plusbevacizumab as the first-line treatment of metastatic colorectal cancer fromhealthcare system perspective. ...
Economic and developmental impacts of FDA designations: a systematic review and meta-analysis [0.03%]
美国食品药品管理局指定的经济和开发影响：系统评价和meta分析
Joab Williamson,Syed Shahzad Hasan,Vijay S Gc
Joab Williamson
Introduction: U.S. FDA designations: Breakthrough Therapy (BTD), Fast Track (FTD), Orphan Drug (ODD), and Regenerative Medicine Advanced Therapy (RMAT) aim to expedite drug development, yet their combined economic and dev...
Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis [0.03%]
美国早期阿尔茨海默病医疗保险受益人使用乐健美单抗的预算影响：亚组分析
Vassiki Sanogo,Reem Dhayan Saud Almutairi,Vakaramoko Diaby
Vassiki Sanogo
Background: In 2024, Alzheimer's disease affected approximately 6.9 million Americans aged 65 and older. Current therapies include acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor inhibitors, and monoclonal ...
Valuing prevention: lessons and recommendations from a Dutch expert committee [0.03%]
重视预防：荷兰专家委员会的经验与启示
Adriënne Rotteveel,Saskia Knies,Ardine de Wit et al.
Adriënne Rotteveel et al.
Introduction: Countries have been struggling with investments in prevention. How to obtain insight in the costs, benefits, and budgetary impacts of investments in prevention? And how to weigh investments in prevention aga...
Willingness to pay for a quality-adjusted life year (QALY) in Pakistan: implications for health policy [0.03%]
巴基斯坦的健康政策中质量调整生命年的支付意愿的影响：质量调整生命年的支付意愿分析
Faizur Rehman,Muhammad Wasay Shahid,Mehran Riaz et al.
Faizur Rehman et al.
Objectives: Allocating healthcare resources in developing countries like Pakistan is constrained by economic limitations and uneven distribution. Therefore, in this study, we aimed to investigate the Willingness to Pay (W...
Unleashing economic potential of AI-driven technology to prevent adverse events and sub-optimal treatment [0.03%]
释放人工智能驱动技术的经济潜力以预防不良事件和次优治疗
L Maas,C Contreras-Meca,W Vos et al.
L Maas et al.
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2024 [0.03%]
药物经济学与结果研究专家评论：2024年高影响力文章
Mickaël Hiligsmann,Carolyn Gotay,Jayashri Sankaranarayanan et al.
Mickaël Hiligsmann et al.
Disease burden estimates in economic evaluation studies of respiratory syncytial virus (RSV) maternal immunization: a systematic review [0.03%]
呼吸道合胞病毒(RSV)孕妇免疫经济评估研究中的疾病负担估计值：系统综述
Sophia Aguiar Monteiro Borges,Natacha Regina de Moraes Cerchiari,Erick Ohanesian Polli et al.
Sophia Aguiar Monteiro Borges et al.
Introduction: Recently, new technologies have emerged for the prevention of respiratory syncytial virus (RSV) infections. Reliable epidemiological data are essential for accurately assessing the disease burden and informi...
A cost-effectiveness estimation of the attempted suicide short intervention programme (ASSIP) [0.03%]
自杀未遂短期干预方案的成本效益分析估算
Max Lelie,Riet Parmentier,Eva de Jaegere et al.
Max Lelie et al.
Objective: Patients who have previously attempted suicide are at a substantially increased risk of a repeated attempt. We have conducted a cost-utility analysis of the Attempted Suicide Short Intervention Programme (ASSIP...
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change [0.03%]
面向2050年的跨学科卫生经济学：防治肥胖、不平等和气候变化所致不良健康效应的挑战
Rhiannon Tudor Edwards
Rhiannon Tudor Edwards